Trinean appoints new CEO and secures 2.7 million euro financing
Trinean NV announced the appointment of Philippe Stas as it’s new CEO, succeeding Dr. Marc Zabeau, who remains a member of the board of directors. Simultaneously, Trinean announced that the company has secured 2.7 million euro of growth financing provided by its existing investors.
Prior to joining Trinean, Philippe Stas was CEO of Algonomics NV, a Belgium based biotech service provider, where he ensured the growth and subsequent trade sale of the company to Lonza Group AG in 2009. Since then, he was the director and main driver of Lonza’s Applied Protein Services division in Cambridge (UK). Earlier, Philippe Stas held positions at Perkin Elmer and Keygene. Philippe holds a M.Sc. in Bio-engineering (Brussels Univ.), a M.Sc. in Information Technology (Hasselt Univ.), an MBA (Univ. of Liverpool) and AMP at the Vlerick Management School.
Trinean raised 2.7 million euro to further accelerate the development of its premium analytical platform, comprising highly accurate spectrophotometry instruments, state-ofthe-art analytical software, proprietary disposables for standardized micro-volume sample analysis and highly flexible lab-automation tools.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Water distribution in the fuel cell made visible in 4D - The analysis opens new possibilities for more efficient and thus more cost-effective fuel cells
New deep learning algorithm can pick up genetic mutations and DNA mismatch repair deficiency in colorectal cancers more efficiently - The findings open up the possibility to select patients likely to benefit from targeted therapies at lower costs and with quicker turnaround times as compared to current methods
VWR International Acquires INTERNATIONAL P.B.I. S.p.A. - VWR strengthens its position in Italy
Molecular imaging hack makes cameras 'faster'
DataApex audited for ISO 9001 standards
Brain imaging gives new insight into mental disorders
Pain sensors specialized for specific sensations
Corona research at BESSY II: Two days of measuring operation to find the right key
Sensor to search for artery hardening compounds in blood
Potent, puzzling and (now less) toxic: How antifungal drug works
Merck’s new spin-off to focus on infertility treatment
